Transactivation of the human multidrug resistance (MDR1) gene promoter by p53 mutants

Autor: Kt, Nguyen, Liu B, Kazumitsu Ueda, Mm, Gottesman, Pastan I, Kv, Chin

Publikováno v: Europe PubMed Central

Multidrug resistance in human cancer is associated with overexpression of the MDR1 gene, which encodes a plasma membrane energy-dependent efflux pump termed P-glycoprotein (or the multidrug transporter), which confers cross-resistance to multiple hyd

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::49111146bda9e46563dae7a02d7719f0
https://pubmed.ncbi.nlm.nih.gov/7949467

A bicistronic retrovirus vector containing a picornavirus internal ribosome entry site allows for correction of X-linked CGD by selection for MDR1 expression

Autor: Ra, Sokolic, Sekhsaria S, Sugimoto Y, Whiting-Theobald N, Gf, Linton, Li F, Mm, Gottesman, Harry Malech

Publikováno v: Europe PubMed Central

Chronic granulomatous disease (CGD) is an inherited hematologic disorder involving failure of phagocytic cell oxidase to produce superoxide (O2-.), resulting in recurrent infections. The success of retrovirus gene therapy for hematopoietic diseases w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3280530d4b0dfe50ff13612f837b7df5
http://europepmc.org/abstract/med/8547675

Identification of NanoLuciferase Substrates Transported by Human ABCB1 and ABCG2 and Their Zebrafish Homologs at the Blood-Brain Barrier.

Autor: Quinlan JA; Fischell Department of Bioengineering, University of Maryland, College Park, Maryland (J.A.Q., C.T.I., H.-C.H.); Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland (J.A.Q., S.S., R.W.R., C.C.L., C.T.I., J.R.T., M.M.G.); and Promega Corporation, San Luis Obispo, California (J.R.W., W.Z.)., Sabbineni S; Fischell Department of Bioengineering, University of Maryland, College Park, Maryland (J.A.Q., C.T.I., H.-C.H.); Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland (J.A.Q., S.S., R.W.R., C.C.L., C.T.I., J.R.T., M.M.G.); and Promega Corporation, San Luis Obispo, California (J.R.W., W.Z.)., Robey RW; Fischell Department of Bioengineering, University of Maryland, College Park, Maryland (J.A.Q., C.T.I., H.-C.H.); Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland (J.A.Q., S.S., R.W.R., C.C.L., C.T.I., J.R.T., M.M.G.); and Promega Corporation, San Luis Obispo, California (J.R.W., W.Z.)., Lipsey CC; Fischell Department of Bioengineering, University of Maryland, College Park, Maryland (J.A.Q., C.T.I., H.-C.H.); Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland (J.A.Q., S.S., R.W.R., C.C.L., C.T.I., J.R.T., M.M.G.); and Promega Corporation, San Luis Obispo, California (J.R.W., W.Z.)., Inglut CT; Fischell Department of Bioengineering, University of Maryland, College Park, Maryland (J.A.Q., C.T.I., H.-C.H.); Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland (J.A.Q., S.S., R.W.R., C.C.L., C.T.I., J.R.T., M.M.G.); and Promega Corporation, San Luis Obispo, California (J.R.W., W.Z.)., Thomas JR; Fischell Department of Bioengineering, University of Maryland, College Park, Maryland (J.A.Q., C.T.I., H.-C.H.); Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland (J.A.Q., S.S., R.W.R., C.C.L., C.T.I., J.R.T., M.M.G.); and Promega Corporation, San Luis Obispo, California (J.R.W., W.Z.)., Walker JR; Fischell Department of Bioengineering, University of Maryland, College Park, Maryland (J.A.Q., C.T.I., H.-C.H.); Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland (J.A.Q., S.S., R.W.R., C.C.L., C.T.I., J.R.T., M.M.G.); and Promega Corporation, San Luis Obispo, California (J.R.W., W.Z.)., Zhou W; Fischell Department of Bioengineering, University of Maryland, College Park, Maryland (J.A.Q., C.T.I., H.-C.H.); Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland (J.A.Q., S.S., R.W.R., C.C.L., C.T.I., J.R.T., M.M.G.); and Promega Corporation, San Luis Obispo, California (J.R.W., W.Z.)., Huang HC; Fischell Department of Bioengineering, University of Maryland, College Park, Maryland (J.A.Q., C.T.I., H.-C.H.); Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland (J.A.Q., S.S., R.W.R., C.C.L., C.T.I., J.R.T., M.M.G.); and Promega Corporation, San Luis Obispo, California (J.R.W., W.Z.)., Gottesman MM; Fischell Department of Bioengineering, University of Maryland, College Park, Maryland (J.A.Q., C.T.I., H.-C.H.); Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland (J.A.Q., S.S., R.W.R., C.C.L., C.T.I., J.R.T., M.M.G.); and Promega Corporation, San Luis Obispo, California (J.R.W., W.Z.) mgottesman@nih.gov.

Publikováno v: Molecular pharmacology [Mol Pharmacol] 2024 Nov 18; Vol. 106 (6), pp. 278-286. Date of Electronic Publication: 2024 Nov 18.

A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples.

Autor: Arakawa Y; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Elloumi F; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Varma S; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Khandagale P; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Jo U; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Kumar S; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Roper N; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Reinhold WC; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Robey RW; Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Takebe N; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Gottesman MM; Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Thomas CJ; National Institutes of Health, Rockville, Maryland., Boeva V; Department of Computer Science, Institute for Machine Learning, ETH Zurich, Zurich, Switzerland., Berruti A; Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, Medical Oncology Unit, University of Brescia, Azienda Socio Sanitaria Territoriale (ASST) Spedali Civili, Brescia, Italy., Abate A; Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy., Tamburello M; Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy., Sigala S; Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy., Hantel C; Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich, and University of Zurich, Zürich, Switzerland.; Medizinische Klinik und Poliklinik III, University Hospital Carl Gustav Carus Dresden, Dresden, Germany., Weigand I; Division of Endocrinology and Diabetology, Department of Internal Medicine I, University Hospital, University of Würzburg, Würzburg, Germany., Wierman ME; Department of Medicine-Endocrinology/Metabolism/Diabetes, University of Colorado, Anschutz Medical Campus, Aurora, Colorado., Kiseljak-Vassiliades K; Department of Medicine-Endocrinology/Metabolism/Diabetes, University of Colorado, Anschutz Medical Campus, Aurora, Colorado., Del Rivero J; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Pommier Y; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

Publikováno v: Cancer research communications [Cancer Res Commun] 2024 Sep 01; Vol. 4 (9), pp. 2384-2398.

Carrier-Free, Amorphous Verteporfin Nanodrug for Enhanced Photodynamic Cancer Therapy and Brain Drug Delivery.

Autor: Quinlan JA; Fischell Department of Bioengineering, University of Maryland, College Park, MD, 20742, USA.; Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA., Inglut CT; Fischell Department of Bioengineering, University of Maryland, College Park, MD, 20742, USA.; Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA., Srivastava P; Fischell Department of Bioengineering, University of Maryland, College Park, MD, 20742, USA., Rahman I; Fischell Department of Bioengineering, University of Maryland, College Park, MD, 20742, USA.; Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA., Stabile J; Fischell Department of Bioengineering, University of Maryland, College Park, MD, 20742, USA., Gaitan B; Fischell Department of Bioengineering, University of Maryland, College Park, MD, 20742, USA., Arnau Del Valle C; Fischell Department of Bioengineering, University of Maryland, College Park, MD, 20742, USA., Baumiller K; Fischell Department of Bioengineering, University of Maryland, College Park, MD, 20742, USA., Gaur A; Fischell Department of Bioengineering, University of Maryland, College Park, MD, 20742, USA., Chiou WA; Advanced Imaging and Microscopy Laboratory, Maryland Nano Center, University of Maryland, College Park, MD, 20742, USA., Karim B; Molecular Histopathology Laboratory, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, 21701, USA., Connolly N; Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, 21201, USA., Robey RW; Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA., Woodworth GF; Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.; Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, MD, 21201, USA., Gottesman MM; Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA., Huang HC; Fischell Department of Bioengineering, University of Maryland, College Park, MD, 20742, USA.; Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.

Publikováno v: Advanced science (Weinheim, Baden-Wurttemberg, Germany) [Adv Sci (Weinh)] 2024 May; Vol. 11 (17), pp. e2302872. Date of Electronic Publication: 2024 Mar 06.